Navigation Links
Initial trials on new ovarian cancer tests exhibit extremely high accuracy
Date:8/11/2010

Scientists at the Georgia Institute of Technology have attained very promising results on their initial investigations of a new test for ovarian cancer. Using a new technique involving mass spectrometry of a single drop of blood serum, the test correctly identified women with ovarian cancer in 100 percent of the patients tested. The results can be found online in the journal Cancer Epidemiology, Biomarkers, & Prevention Research.

"Because ovarian cancer is a disease of relatively low prevalence, it's essential that tests for it be extremely accurate. We believe we may have developed such a test," said John McDonald, chief research scientist at the Ovarian Cancer Institute (Atlanta) and professor of biology at Georgia Tech.

The measurement step in the test, developed by the research group of Facundo Fernandez, associate professor in the School of Chemistry and Biochemistry at Tech, uses a single drop of blood serum, which is vaporized by hot helium plasma. As the molecules from the serum become electrically charged, a mass spectrometer is used to measure their relative abundance. The test looks at the small molecules involved in metabolism that are in the serum, known as metabolites. Machine learning techniques developed by Alex Gray, assistant professor in the College of Computing and the Center for the Study of Systems Biology, were then used to sort the sets of metabolites that were found in cancerous plasma from the ones found in healthy samples. Then, McDonald's lab mapped the results between the metabolites found in both sets of tissue to discover the biological meaning of these metabolic changes.

The assay did extremely well in initial tests involving 94 subjects. In addition to being able to generate results using only a drop of blood serum, the test proved to be 100 percent accurate in distinguishing sera from women with ovarian cancer from normal controls. In addition it registered neither a single false positive nor a false negative

The group is currently in the midst of conducting the next set of assays, this time with 500 patients.

"The caveat is we don't currently have 500 patients with the same type of ovarian cancer, so we're going to look at other types of ovarian cancer," said Fernandez. "It's possible that there are also signatures for other cancers, not just ovarian, so we're also going to be using the same approach to look at other types of cancers. We'll be working with collaborators in Atlanta and elsewhere."

In addition to having a relatively low prevalence ovarian cancer is also asymptomatic in the early stages. Therefore, if further testing confirms the ability to accurately detect ovarian cancer by analyzing metabolites in the serum of women, doctors will be able detect the disease early and save many lives.


'/>"/>

Contact: David Terraso
david.terraso@comm.gatech.edu
404-385-2966
Georgia Institute of Technology
Source:Eurekalert

Related biology news :

1. HSBC Climate Partnership yields initial research findings
2. Nervy research: Researchers take initial look at ion channels in a model system
3. Fish fend off invading germs with an initial response similar to the one found in people
4. Faster, cheaper way to find disease genes in human genome passes initial test
5. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
6. International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury
7. Genetic testing not cost-effective in guiding initial dosing of common blood thinner
8. Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults
9. Pioneering Use of Mobile Technology to Conduct Clinical Trials in Emerging Economies
10. UF oncologists fight leukemia with two-pronged therapy, clinical trials planned
11. Pitt gets $12 million DoD contract for regenerative medicine treatment trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
(Date:1/23/2017)...  The latest mobile market research from Acuity Market ... The quarterly average price of a biometric smartphone decreased ... 2016.  There are now 120 sub-$150 models on the ... just 28 a year ago at an average price ... Most , Acuity Market Intelligence Principal, "Biometric Smartphones are ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... (NASDAQ: VWR), the leading global independent provider of product and ... financial results for the fourth quarter and full year ended ... 4Q16 record quarterly net sales of $1.13 billion, up 1.6% ... 4Q16 EMEA-APAC segment net sales increased 0.4%, ... sales increased 2.5%, or down 0.9% on an organic basis, ...
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
Breaking Biology Technology: